Company intelligence / Profile preview
Zehna Therapeutics
Cleveland, Ohio, United Stateszehnatx.com ↗
- Ownership
- Private
- Employees
- ~6
- Development stage
- Preclinical
01
Overview
Zehna has demonstrated statistically significant reduction in clinical markers of kidney function and fibrosis with its lead compound in an adenine-induced CKD animal model. The company is preparing for IND submission and aims to reach proof-of-principle in humans by the end of its current funding cycle.
- Therapeutic areas
- CardiovascularNephrology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Zehna Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zehna Therapeutics.